Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Rigel Pharmaceuticals shares valued at $42,595 were sold by Schorno Dean L on Feb 04 ’25. At $20.92 per share, Schorno Dean L sold 2,036 shares. The insider’s holdings dropped to 58,969 shares worth approximately $1.12 million following the completion of this transaction.
Also, Schorno Dean L sold 1,734 shares, netting a total of over 38,020 in proceeds. Following the sale of shares at $21.93 each, the insider now holds 57,235 shares.
Before that, Santos David A had sold 2,125 shares from its account. In a trade valued at $44,457, the EVP, Chief Commercial Officer traded Rigel Pharmaceuticals shares for $20.92 each. Upon closing the transaction, the insider’s holdings decreased to 2,125 shares, worth approximately $1.01 million.
Analysts at Citigroup downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early June. As of June 08, 2022, Piper Sandler has decreased its “an Overweight” rating to a “Neutral” for RIGL. Earlier on June 08, 2022, Cantor Fitzgerald downgraded its rating. Their new recommendation was “a Neutral” for RIGL stock which previously was a “an Overweight”.
Analyzing RIGL Stock Performance
On last trading session, Rigel Pharmaceuticals [NASDAQ: RIGL] rose 1.50% to $18.93. The stock’s lowest price that day was $18.65, but it reached a high of $19.18 in the same session. During the last five days, there has been a surge of approximately 0.91%. Over the course of the year, Rigel Pharmaceuticals shares have jumped approximately 125.09%. Shares of the company reached a 52-week high of $25.42 on 05/07/25 and a 52-week low of $15.50 on 04/09/25.
Support And Resistance Levels for Rigel Pharmaceuticals (RIGL)
According to the 24-hour chart, there is a support level at 18.66, which, if violated, would cause prices to drop to 18.39. In the upper region, resistance lies at 19.19. The next price resistance is at 19.45. RSI (Relative Strength Index) is 44.96 on the 14-day chart, showing neutral technical sentiment.
Is Rigel Pharmaceuticals subject to short interest?
Stocks of Rigel Pharmaceuticals saw a sharp rise in short interest on 2025-06-13 jumping by 15197.0 shares to 2.1 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 2.08 million shares. A jump of 0.72% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.55 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.55.
Which companies own the most shares of Rigel Pharmaceuticals (RIGL)?
In terms of Rigel Pharmaceuticals share price expectations, FactSet research, analysts set an average price target of 1.5 in the next 12 months, down nearly -91.96% from the previous closing price of $18.65. Analysts anticipate Rigel Pharmaceuticals stock to reach 2 by 2025, with the lowest price target being 1. In spite of this, 5 analysts ranked Rigel Pharmaceuticals stock as Buy at the end of 2025. On March 23, 2022, B. Riley Securities assigned a price target of “a Neutral” to the stock and initiated coverage with a $4.
